COVID-19 Vaccines

COVID-19 Vaccine

Vaccine Eligibility

First and second doses

These individuals are currently eligible for first or second doses of a COVID-19 vaccine.

Dose Eligible population How to access vaccine

1st or 2nd dose (2nd dose 8 weeks after 1st dose)

Children must be five years old or older at the time of vaccination. Eligibility is based on date of birth and will be confirmed at the time of vaccination.

Dose Eligible population How to access vaccine

1st or 2nd dose (8 weeks after 1st dose)

Check what date you are eligible for a second dose

Individuals who are age 12 and older.

Eligibility is based on date of birth and will be confirmed at the time of the appointment.

Third or booster doses

These individuals are currently eligible for third or booster doses of a COVID-19 vaccine.

Dose Eligible population How to access vaccine

Booster dose
6 months (168 days) or more after 2nd dose

Check what date you are eligible for a booster dose

Individuals age 12 to 17.

Eligibility is based on date of birth and will be confirmed at the time of the appointment. Plan to get your vaccine after your 12th birthday.

Dose Eligible population How to access vaccine

3 months (84 days) or more after 2nd dose

Check what date you are eligible for a booster dose

Individuals age 18 and older

Eligibility is based on date of birth and will be confirmed at the time of the appointment. Plan to get your vaccine after your 18th birthday.

Dose Eligible population How to access vaccine

Booster dose 3 months (84 days) or more after 2nd dose

Check what date you are eligible for a booster dose

Pregnant individuals

Dose Eligible population How to access vaccine

Booster dose, 3 months (84 days)  or more after 2nd dose

Check what date you are eligible for a booster dose

Individuals who received a complete series of a viral vector vaccine (two doses of AstraZeneca vaccine or one dose of J & J/Janssen vaccine)

Individuals can receive an mRNA vaccine (Pfizer, where supply is available, or Moderna) for a booster dose.

Dose Eligible population How to access vaccine

3rd dose, 8 weeks (56 days) or more after 2nd dose

Check what date you are eligible for a booster dose

Immunocompromised populations age 5+:

  • Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome.
  • Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Individuals receiving active treatment (including those who have completed treatment within the last three months) for solid tumour or hematologic malignancies (e.g.: chemotherapy, targeted therapies, immunotherapy).
  • Recipients of solid-organ transplant and taking immunosuppressive therapy.
  • Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Individuals receiving active treatment with the following categories of immunosuppressive therapies, anti-B cell therapies such as monoclonal antibodies targeting CD19 CD20 and CD22 (including those who have completed treatment within 12 months), high dose corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor inhibitors and other biologic agents that are significantly immunosuppressive.
  • Individuals receiving dialysis (hemodialysis or peritoneal dialysis)

Eligible individuals can show a current prescription receipt from a pharmacy or the medication bottle or packaging that includes the date of prescription, their first and last name, and the address and phone number of the pharmacy to receive their third dose of COVID-19 vaccine. See list of eligible immunosuppressive medications. Clinical staff will verify eligibility at vaccine clinics.

If eligible individuals do not have a prescription, or the drug is not listed by Ministry, a referral form from the treating health care provider (doctor, nurse practitioner, specialist, hospital specialty program) must be provided at the clinic to receive a third dose of a COVID-19 vaccine.

Timing of the third dose should be decided with the treating provider in order to optimize immune response and minimize delays in management of underlying conditions.
Dose Eligible population How to access vaccine

3rd dose, 3 months (84 days) or more after 2nd dose

Check what date you are eligible for a booster dose

  • Residents of high-risk congregate settings including:
  • long-term care homes
  • high-risk licensed retirement homes
  • First Nations elder care lodges

Seniors living in congregate settings including:

  • retirement homes
  • assisted living facilities
  • chronic care hospitals
  • congregate seniors’ apartment buildings
Registration through facility 

Fourth doses

The following individuals are currently eligible for fourth doses of a COVID-19 vaccine.

Dose Eligible population How to access vaccine

4th dose
5 months (140 days) or more after 3rd dose

Individuals age 60 and older.
Eligibility is based on date of birth and will be confirmed at the time of the appointment.

Dose Eligible population How to access vaccine

4th dose
5 months (140 days) or more after 3rd dose

First Nation, Inuit and Metis individuals and their non-Indigenous household members who are age 18 and older. Eligibility is based on date of birth and will be confirmed at the time of the appointment.

Dose Eligible population How to access vaccine

4th dose, 3 months (84 days) or more after 3rd dose

Residents of high-risk congregate settings including:

  • long-term care homes
  • high-risk licensed retirement homes
  • First Nations elder care lodges

Older adults living in other congregate settings providing assisted-living and health services.

Registration through facility

Individuals eligible for 3-dose primary series of the COVID-19 vaccine are eligible for a fourth dose.

Dose Eligible population How to access vaccine

4th dose

Age 18+: 3 months (84 days) or more after 3rd dose

Age 12-17: 6 months (168 days) or more after 3rd dose

Immunocompromised populations age 12+:

  • Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome.
  • Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Individuals receiving active treatment (including those who have completed treatment within the last three months) for solid tumour or hematologic malignancies (e.g.: chemotherapy, targeted therapies, immunotherapy).
  • Recipients of solid-organ transplant and taking immunosuppressive therapy.
  • Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Individuals receiving active treatment with the following categories of immunosuppressive therapies, anti-B cell therapies such as monoclonal antibodies targeting CD19 CD20 and CD22 (including those who have completed treatment within 12 months), high dose corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor inhibitors and other biologic agents that are significantly immunosuppressive.
  • Individuals receiving dialysis (hemodialysis or peritoneal dialysis)

Eligible individuals can show a current prescription receipt from a pharmacy or the medication bottle or packaging that includes the date of prescription, their first and last name, and the address and phone number of the pharmacy to receive their fourth dose of COVID-19 vaccine. See list of eligible immunosuppressive medications. Clinical staff will verify eligibility at vaccine clinics.

If eligible individuals do not have a prescription, or the drug is not listed by Ministry, a referral form from the treating health care provider (doctor, nurse practitioner, specialist, hospital specialty program) must be provided at the clinic to receive a fourth dose of a COVID-19 vaccine.

Timing of the fourth dose should be decided with the treating provider in order to optimize immune response and minimize delays in management of underlying conditions.

Fifth doses

The following individuals are currently eligible for fifth doses of a COVID-19 vaccine.

Individuals who received a 3-dose primary series of the COVID-19 vaccine are eligible for a second booster (5th dose) only if they fall into one of the groups below.

Dose Eligible population How to access vaccine

5th dose

5 months (140 days) or more after 4th dose

Immunocompromised individuals who received a 3-dose primary series and must also fit into one of the following groups:

  • Age 60+
  • First Nation, Inuit and Metis individuals and their non-Indigenous household members (18+)
  • Residents of Long-Term Care Homes, Retirement Homes, Elder Care Lodges and Older Adults Living in other Congregate Settings

Immunocompromised individuals:

  • Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome.
  • Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Individuals receiving active treatment (including those who have completed treatment within the last three months) for solid tumour or hematologic malignancies (e.g.: chemotherapy, targeted therapies, immunotherapy).
  • Recipients of solid-organ transplant and taking immunosuppressive therapy.
  • Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Individuals receiving active treatment with the following categories of immunosuppressive therapies, anti-B cell therapies such as monoclonal antibodies targeting CD19 CD20 and CD22 (including those who have completed treatment within 12 months), high dose corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor inhibitors and other biologic agents that are significantly immunosuppressive.
  • Individuals receiving dialysis (hemodialysis or peritoneal dialysis)

Eligible individuals can show a current prescription receipt from a pharmacy or the medication bottle or packaging that includes the date of prescription, their first and last name, and the address and phone number of the pharmacy to receive their fourth dose of COVID-19 vaccine. See list of eligible immunosuppressive medications. Clinical staff will verify eligibility at vaccine clinics.

If eligible individuals do not have a prescription, or the drug is not listed by Ministry, a referral form from the treating health care provider (doctor, nurse practitioner, specialist, hospital specialty program) must be provided at the clinic to receive a fourth dose of a COVID-19 vaccine.

Timing of the fifth dose should be decided with the treating provider in order to optimize immune response and minimize delays in management of underlying conditions.

After vaccination

It is vital that everyone, even those who have been vaccinated, continue practicing public health measures including:  

  • staying home if you have any COVID-19 symptoms
  • getting tested for COVID-19 if you have symptoms or have been in close contact with a confirmed positive case of COVID-19, if eligible.
  • keeping your distance from others
  • wearing a mask or face covering
  • washing hands frequently

If you have general questions about the COVID-19 vaccine: